Topic: Policy: Orphan Drug Policy Reform

Applying the Results of Comparative Effectiveness Research to Control Drug Costs: Policy Options for California

Mar 2023 | Policy Paper

This paper illustrates how comparative effectiveness research can be used by policymakers and health insurers in California to address rising drug costs by aligning spending with the degree of benefit a treatment provides.  ICER received a grant from the California Health Care Foundation (CHCF) to develop the White Paper. Date of publication: March 2023 For […]

Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity

Mar 2023 | Policy Paper

ICER has received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide. Join us on March 21st for a webinar explaining […]

Evaluating Reforms to Orphan Drug Development, Pricing, and Coverage

Apr 2022 | Policy Paper

This White Paper examines the potential risks and advantages of reforms to current policies related to orphan drug development, pricing, and coverage. The White Paper does not advocate for specific policy proposals. Instead, it analyzes the potential benefits and risks of reforms that might serve to reshape the incentives for orphan drug development in a […]